No association between Factor V. Leiden mutation and coronary heart disease or carotid intima media thickness: The NHLBI family heart study

Thrombosis Research

Volumn 89, Issue 6, 1998, Pages 289-293

  Garg, Uttam C ^a   Arnett, Donna K ^b   Evans, Greg ^c   Eckfeldt, John H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Carotid intima media thickness; Coronary heart disease; Factor V. Leiden mutation; Resistance to protein C

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; FAMILY HISTORY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ADULT; AGE OF ONSET; AGED; CAROTID ARTERIES; CORONARY DISEASE; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; TUNICA MEDIA;

EID: 0032520739     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00019-X     Document Type: Article

References (18)

1. Dahlbäck B., Carlsson M. Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C Proc Natl Acad Sci. 90:1993;1004-1008.
2. Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 330:1994;517-522.
3. Griffin J.H., Evatt B., Wideman C., Fernandez J.A. Anticoagulant protein C pathway defect in majority of thrombophilic patients. Blood. 82:1993;1989-1993.
4. Koster T., Rosendaal F.R., de Ronde H., Briet E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study Lancet. 342:1993;1503-1506.
5. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:1995;912-917.
6. Ma D.D.F., Williams B.G., Aboud M.R., Isbister J.P. Activated protein C resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic. Aust NZ J Med. 25:1995;151-154.
7. Biasiutti F.D., Furlan C.M., Sulzer I., Binder B.R., Lammle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinol. 6:1995;456-459.
8. Holm J., Zoller B., Berntorp E., Erhardt L., Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Inter Med. 239:1996;221-226.
9. 506 to Gln) mutation in young survivors of myocardial infarction. Thromb Haemost. 75:1996;701-702.
10. Prohasks W., Mannebach H., Schmidt M., Gleichmann U., Kleesiek K. Evidence against heterozygous coagulation factor V 1691 G to A mutation with resistance to activated protein C being a risk factor for coronary heart disease and myocardial infarction. J Mol Med. 73:1995;521-524.
11. Higgins M., Province M., Heiss G., Eckfeldt J., Ellison R.C., Folsom A., Rao D.C., Sprafka J.M., Williams R., for the NHLBI Family Heart Study Investigators The NHLBI Family Heart Study. Objectives and design Am J Epidemiol. 143(12):1996;1219-1228.
12. SAS Institute Inc SAS/STAT® User's Guide, Version 6, Fourth Edition, Volume 2. 1989;SAS Institute Inc, Cary, NC.
13. Cortellaro M., Baldassarre D., Cofrancesco E., Tremoli E., Colombo A., Boschetti C., Paoletti R. Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease. Stroke. 27:1996;450-454.
14. Agewall S., Wikstrand J., Suurkula M., Tengborn L., Fagerberg B. Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk from atherosclerotic disease. Blood Coagul Fibrinol. 5:1994;895-904.
15. Sosef M.N., Bosch J.G., Van Oostayen J., Visser T., Reiber J.H., Rosendaal F.R. Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness. Thromb Haemost. 72:1994;250-254.
16. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., Van Der Velden P.A., Reitsma P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
17. Montaruli B., Voorberg J., Tamponi G., Borchiellini A., Muleo G., Pannocchia A., Van Mourik J.A., Schinco P. Arterial and venous thrombosis in two Italian families with the factor V Arg506 to Gln mutation. Eur J Haematology. 57:1996;96-100.
18. Rosendaal F.R., Siscovick D.S., Schwartz S.M., Beverly R.K., Psaty B.M., Longstreth W.T. Jr., Raghunathan T.E., Koepsell T.D., Reitsma P.H. Factor V Leiden (Resistance to Activated Protein C) Increases the Risk of Myocardial Infarction in Young Women. Blood. 89(8):1997;2817-2821.